<SEC-DOCUMENT>0001193125-24-270867.txt : 20241205
<SEC-HEADER>0001193125-24-270867.hdr.sgml : 20241205
<ACCEPTANCE-DATETIME>20241204185301
ACCESSION NUMBER:		0001193125-24-270867
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20241203
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241205
DATE AS OF CHANGE:		20241204

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CVS HEALTH Corp
		CENTRAL INDEX KEY:			0000064803
		STANDARD INDUSTRIAL CLASSIFICATION:	RETAIL-DRUG STORES AND PROPRIETARY STORES [5912]
		ORGANIZATION NAME:           	07 Trade & Services
		IRS NUMBER:				050494040
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-01011
		FILM NUMBER:		241527386

	BUSINESS ADDRESS:	
		STREET 1:		ONE CVS DR.
		CITY:			WOONSOCKET
		STATE:			RI
		ZIP:			02895
		BUSINESS PHONE:		4017651500

	MAIL ADDRESS:	
		STREET 1:		ONE CVS DR.
		CITY:			WOONSOCKET
		STATE:			RI
		ZIP:			02895

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CVS CAREMARK CORP
		DATE OF NAME CHANGE:	20070509

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CVS/CAREMARK CORP
		DATE OF NAME CHANGE:	20070322

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CVS CORP
		DATE OF NAME CHANGE:	19970128
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d910747d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cvs="http://www.cvshealth.com/20241203" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityRegistrantName" name="dei:EntityRegistrantName" contextRef="duration_2024-12-03_to_2024-12-03">CVS HEALTH Corp</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2024-12-03_to_2024-12-03" id="ixv-280">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2024-12-03_to_2024-12-03">0000064803</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="cvs-20241203.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2024-12-03_to_2024-12-03"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-12-03</xbrli:startDate> <xbrli:endDate>2024-12-03</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2024-12-03_to_2024-12-03" id="ixv-291">8-K</ix:nonNumeric></span></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 OR 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of The Securities Exchange Act of 1934</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2024-12-03_to_2024-12-03" format="ixt:datemonthdayyearen" id="ixv-292">December&#160;3, 2024</ix:nonNumeric></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">
<img src="g910747g1204104159153.jpg" alt="LOGO" style="width:1.10972in;height:0.211806in"/></p> <p style="margin-top:1pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_EntityRegistrantName">CVS HEALTH CORPORATION</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2024-12-03_to_2024-12-03" format="ixt-sec:stateprovnameen" id="ixv-293">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2024-12-03_to_2024-12-03" id="ixv-294">001-01011</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2024-12-03_to_2024-12-03" id="ixv-295">05-0494040</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2024-12-03_to_2024-12-03" id="ixv-296">One CVS Drive</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2024-12-03_to_2024-12-03" id="ixv-297">Woonsocket</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2024-12-03_to_2024-12-03" format="ixt-sec:stateprovnameen" id="ixv-298">Rhode Island</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2024-12-03_to_2024-12-03" id="ixv-299">02895</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2024-12-03_to_2024-12-03" id="ixv-300">(401)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2024-12-03_to_2024-12-03" id="ixv-301">765-1500</ix:nonNumeric></span></p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Former name or former address, if changed since last report: N/A</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2024-12-03_to_2024-12-03" format="ixt-sec:boolballotbox" id="ixv-302">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2024-12-03_to_2024-12-03" format="ixt-sec:boolballotbox" id="ixv-303">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2024-12-03_to_2024-12-03" format="ixt-sec:boolballotbox" id="ixv-304">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2024-12-03_to_2024-12-03" format="ixt-sec:boolballotbox" id="ixv-305">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2024-12-03_to_2024-12-03" id="ixv-306">Common Stock, par value $0.01 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2024-12-03_to_2024-12-03" id="ixv-307">CVS</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2024-12-03_to_2024-12-03" format="ixt-sec:exchnameen" id="ixv-308">New York Stock Exchange</ix:nonNumeric></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2024-12-03_to_2024-12-03" format="ixt-sec:boolballotbox" id="ixv-309">&#9744;</ix:nonNumeric>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Section&#160;8 - Other Events </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;8.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;3, 2024, CVS Health Corporation, a Delaware corporation (the &#8220;Company&#8221;), entered into an Underwriting Agreement (the &#8220;Underwriting Agreement&#8221;) with Barclays Capital Inc., Citigroup Global Markets Inc. and Goldman Sachs&#160;&amp; Co. LLC, as representatives of the several underwriters named in Schedule I thereto (collectively, the &#8220;Underwriters&#8221;), pursuant to which the Company agreed to issue and sell to the Underwriters $2,250,000,000 aggregate principal amount of its 7.000% Series A Junior Subordinated Notes due 2055 (the &#8220;Series A Junior Subordinated Notes&#8221;) and $750,000,000 aggregate principal amount of its 6.750% Series B Junior Subordinated Notes due 2054 (together with the Series A Junior Subordinated Notes, the &#8220;Notes&#8221;). The Notes were offered pursuant to the Company&#8217;s Registration Statement on <span style="white-space:nowrap"><span style="white-space:nowrap">Form&#160;S-3ASR,&#160;File&#160;No.&#160;333-272200,&#160;dated</span></span> May&#160;25, 2023 (the &#8220;Registration Statement&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The closing of the sale of the Notes is expected to occur on December&#160;10, 2024, subject to the satisfaction of customary closing conditions contained in the Underwriting Agreement. The net proceeds to the Company from the sale of the Notes, after deducting the Underwriters&#8217; discounts and the estimated offering expenses payable by the Company, are expected to be approximately $2,963,075,700. A copy of the Underwriting Agreement is filed as Exhibit 1.1 to this Current Report on <span style="white-space:nowrap">Form&#160;8-K&#160;and</span> is incorporated herein by reference and incorporated by reference into the Registration Statement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Information Regarding Forward Looking Statements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Current Report on Form <span style="white-space:nowrap">8-K</span> contains forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by or on behalf of the Company. By their nature, all forward-looking statements are not guarantees of future performance or results and are subject to risks and uncertainties that are difficult to predict and/or quantify. Actual results may differ materially from those contemplated by the forward-looking statements due to the risks and uncertainties described in the Company&#8217;s Securities and Exchange Commission filings, including those set forth in the Risk Factors section and under the heading &#8220;Cautionary Statement Concerning Forward-Looking Statements&#8221; in the Company&#8217;s most recently filed Annual Report on Form <span style="white-space:nowrap">10-K,</span> Quarterly Reports on Form <span style="white-space:nowrap">10-Q</span> for the quarterly periods ended March&#160;31, 2024, June&#160;30, 2024 and September&#160;30, 2024 and Current Reports on Form <span style="white-space:nowrap">8-K.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You are cautioned not to place undue reliance on the Company&#8217;s forward-looking statements. The Company&#8217;s forward-looking statements are and will be based upon management&#8217;s then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements. The Company does not assume any duty to update or revise forward-looking statements, whether as a result of new information, future events, uncertainties or otherwise. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Section&#160;9 - Financial Statements and Exhibits </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">(d)</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left"><span style="text-decoration:underline">Exhibits</span>. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exhibits to this Current Report on Form <span style="white-space:nowrap">8-K</span> are as follows: </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">INDEX TO EXHIBITS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:95%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">1.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d910747dex11.htm">Underwriting Agreement, dated December 3, 2024, between CVS Health Corporation and Barclays Capital Inc., Citigroup Global Markets Inc. and Goldman Sachs&#160;&amp; Co. LLC, as representatives of the several Underwriters named in Schedule I thereto. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document).</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:45%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">CVS HEALTH CORPORATION</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#8194;Date: December 4, 2024</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Thomas F. Cowhey</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Thomas F. Cowhey</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Executive Vice President and Chief Financial Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d910747dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CVS HEALTH CORPORATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>$2,250,000,000 7.000% Series A Junior Subordinated Notes due 2055 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>$750,000,000 6.750% Series B Junior Subordinated Notes due 2054 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Underwriting Agreement </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">December&nbsp;3, 2024 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Barclays Capital Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As Representatives of the several Underwriters </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">named in <U>Schedule I</U> hereto </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Barclays
Capital Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">745 Seventh Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10019
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Citigroup Global Markets Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">388 Greenwich Street
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10013 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Goldman Sachs&nbsp;&amp; Co.
LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">200 West Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10282 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CVS Health Corporation,
a Delaware corporation (the &#147;<B>Company</B>&#148;), proposes to issue and sell $2,250,000,000 aggregate principal amount of its 7.000% Series A Junior Subordinated Notes due 2055 (the &#147;<B>Series A Junior Subordinated Notes</B>&#148;) and
$750,000,000 aggregate principal amount of its 6.750% Series B Junior Subordinated notes due 2054 (the &#147;<B>Series B Junior Subordinated Notes</B>&#148; and, together with the Series A Junior Subordinated Notes, the<B>
</B>&#147;<B>Notes</B>&#148;) to the several underwriters named on <U>Schedule I</U> hereto (the &#147;<B>Underwriters</B>&#148;), for which Barclays Capital Inc., Citigroup Global Markets Inc. and Goldman Sachs&nbsp;&amp; Co. LLC are acting as
representatives (the &#147;<B>Representatives</B>&#148;). The Notes will (a)&nbsp;have terms and provisions which are summarized in the Disclosure Package as of the Applicable Time and the Prospectus dated as of the date hereof (each as defined in
Section&nbsp;1(a) hereof) and (b)&nbsp;be issued pursuant to the Subordinated Indenture dated as of May&nbsp;25, 2007 (the &#147;<B>Indenture</B>&#148;) between the Company (formerly known as &#147;CVS Caremark Corporation&#148;) and The Bank of New
York Mellon Trust Company, N.A. (formerly known as The Bank of New York Trust Company, N.A.), as trustee (the &#147;<B>Trustee</B>&#148;). This agreement (this &#147;<B>Agreement</B>&#148;) is to confirm the agreement concerning the purchase of the
Notes from the Company by the Underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.&#8195;<I>Representations, Warranties and Agreements of the Company</I>. The Company
represents and warrants to, and agrees with, each Underwriter that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;An &#147;automatic shelf registration
statement&#148; (as defined in Rule 405 under the Securities Act of 1933, as amended (the &#147;<B>Securities Act</B>&#148;)) on Form <FONT STYLE="white-space:nowrap">S-3</FONT> in respect of the Notes (File
<FONT STYLE="white-space:nowrap">No.&nbsp;333-272200)</FONT> (i) has been prepared by the Company in conformity with the requirements of the Securities Act and the rules and regulations (the &#147;<B>Rules and Regulations</B>&#148;) of the
Securities and Exchange Commission (the &#147;<B>Commission</B>&#148;) thereunder, (ii)&nbsp;has been filed with the Commission under the Securities Act not earlier than the date that is three years prior to the Closing Date and (iii)&nbsp;upon its
filing with the Commission, automatically became and is effective under the Securities Act. Copies of such registration statement and any amendment thereto (excluding exhibits to such registration statement but including all documents incorporated
by reference in each prospectus contained therein) have been delivered by the Company to the Representatives; and no other document with respect to such registration statement or any such document incorporated by reference therein has heretofore
been filed or transmitted for filing with the Commission. For purposes of this Agreement, the following terms have the specified meanings: </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Applicable Time</B>&#148; means 6:15 p.m. (New York City time) on
the date of this Agreement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Base Prospectus</B>&#148; means the base prospectus filed as part of the Registration
Statement, in the form in which it has most recently been amended on or prior to the date hereof, relating to the Notes; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;</B><B>Disclosure Package</B>&#148; means, as of the Applicable Time, the most recent Preliminary Prospectus, together
with each Issuer Free Writing Prospectus filed or used by the Company on or before the Applicable Time and identified on <U>Schedule II</U> hereto, other than a road show that is an Issuer Free Writing Prospectus under Rule 433 of the Rules and
Regulations; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Effective Date</B>&#148; means any date as of which any part of the Registration Statement or any
post-effective amendment thereto relating to the Notes became, or is deemed to have become, effective under the Securities Act in accordance with the Rules and Regulations (including pursuant to Rule 430B of the Rules and Regulations); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Final Term Sheet</B>&#148; means the term sheet prepared pursuant to Section&nbsp;4(a) of this Agreement and
substantially in the form attached in <U>Schedule III</U> hereto; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Issuer Free Writing Prospectus</B>&#148; means
each &#147;free writing prospectus&#148; (as defined in Rule 405 of the Rules and Regulations) prepared by or on behalf of the Company or used or referred to by the Company in connection with the offering of the Notes, including the Final Term Sheet
and any other Issuer Free Writing Prospectus identified on <U>Schedule II</U> hereto; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Preliminary
Prospectus</B>&#148; means any preliminary prospectus relating to the Notes, including the Base Prospectus and any preliminary prospectus supplement thereto, included in the Registration Statement or as filed with the Commission pursuant to Rule
424(b) of the Rules and Regulations and provided to the Representatives for use by the Underwriters; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Prospectus</B>&#148; means the final prospectus relating to the Notes, including the Base Prospectus and the final
prospectus supplement thereto relating to the Notes, as filed with the Commission pursuant to Rule 424(b) of the Rules and Regulations and provided to the Representatives for use by the Underwriters; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Registration Statement</B>&#148; means, collectively, the various parts of the above-referenced registration
statement, each as amended as of the Effective Date for such part, including any Preliminary Prospectus and the Prospectus, all exhibits to such registration statement and all documents incorporated by reference therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any reference to &#147;<B>the most recent Preliminary Prospectus</B>&#148; will be deemed to refer to the latest Preliminary Prospectus
included in the Registration Statement or filed pursuant to Rule 424(b) of the Rules and Regulations prior to or on the date hereof (including, for purposes of this Agreement, any documents incorporated by reference therein prior to or on the date
of this Agreement). Any reference to any Preliminary Prospectus or the Prospectus will be deemed to refer to and include any documents incorporated by reference therein pursuant to Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the
Securities Act as of the date of such Preliminary Prospectus or the Prospectus, as the case may be. Any reference to any amendment or supplement to any Preliminary Prospectus or the Prospectus will be deemed to refer to and include any document
filed under the Securities Exchange Act of 1934, as amended (the &#147;<B>Exchange Act</B>&#148;), after the date of such Preliminary Prospectus or the Prospectus, as the case may be, and incorporated by reference in such Preliminary Prospectus or
the Prospectus, as the case may be; and any reference to any amendment to the Registration Statement will be deemed to include any annual report of the Company on Form 10-K filed with the Commission pursuant to Section&nbsp;13(a) or 15(d) of the
Exchange Act after the Effective Date that is incorporated by reference in the Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;The
Commission has not issued any order preventing or suspending the effectiveness of the Registration Statement or preventing or suspending the use of any Preliminary Prospectus, any Issuer Free Writing Prospectus or the Prospectus; and no proceeding
for any such purpose or pursuant to Section&nbsp;8A of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">
Securities Act against the Company or related to the offering has been instituted or, to the Company&#146;s knowledge, threatened by the Commission. The Commission has not issued any order
directed to any document incorporated by reference in the most recent Preliminary Prospectus or the Prospectus, and no proceeding has been instituted or, to the Company&#146;s knowledge, threatened by the Commission with respect to any document
incorporated by reference in the most recent Preliminary Prospectus or the Prospectus. The Commission has not notified the Company of any objection to the use of the form of the Registration Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;The Company has been, and continues to be, a &#147;well-known seasoned issuer&#148; (as defined in Rule 405 of the
Rules and Regulations) and has not been, and continues not to be, an &#147;ineligible issuer&#148; (as defined in Rule 405 of the Rules and Regulations), in each case at all times relevant under the Securities Act in connection with the offering of
the Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#8195;The Registration Statement conformed on the Effective Date and conforms, and any amendment to the
Registration Statement filed after the date hereof will conform, in all material respects, to the requirements of the Securities Act and the Rules and Regulations. The most recent Preliminary Prospectus conforms on the date hereof, and the
Prospectus, and any amendment or supplement thereto, will conform as of its date and as of the Closing Date, in all material respects, to the requirements of the Securities Act and the Rules and Regulations. The documents of the Company incorporated
by reference in the most recent Preliminary Prospectus or the Prospectus conformed, and any further documents so incorporated will conform, when filed with the Commission, in all material respects to the requirements of the Exchange Act or the
Securities Act, as applicable, and the Rules and Regulations; and no such documents have been filed with the Commission since the close of business of the Commission on the Business Day immediately prior to the date hereof (other than those
documents disclosed to the Representatives prior to the time of filing). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&#8195;The Registration Statement does not,
as of the date hereof, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading; <I>provided, however,</I> that no representation or
warranty is made as to information contained in or omitted from the Registration Statement in reliance upon and in conformity with written information furnished to the Company through the Representatives by or on behalf of any Underwriter
specifically for inclusion therein (which information is specified in Section&nbsp;12 hereof) or relating to that part of the Registration Statement that constitutes the Statement of Eligibility and Qualifications on Form <FONT
STYLE="white-space:nowrap">T-1</FONT> of the Trustee under the Trust Indenture Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&#8195;The Disclosure Package did
not, as of the Applicable Time, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were
made, not misleading; <I>provided, however,</I> that no representation or warranty is made as to information contained in or omitted from the Disclosure Package in reliance upon and in conformity with written information furnished to the Company
through the Representatives by or on behalf of any Underwriter specifically for inclusion therein (which information is specified in Section&nbsp;12 hereof). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&#8195;The Prospectus, and any amendment or supplement thereto, will not, as of its date and on the Closing Date, contain
any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; <I>provided,
however,</I> that no representation or warranty is made as to information contained in or omitted from the Prospectus in reliance upon and in conformity with written information furnished to the Company through the Representatives by or on behalf of
any Underwriter specifically for inclusion therein (which information is specified in Section&nbsp;12 hereof). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&#8195;The documents of the Company incorporated by reference in the most recent Preliminary Prospectus or the Prospectus
did not, and any further documents incorporated by reference therein will not, when filed with the Commission, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the
statements therein, in the light of the circumstances under which they were made, not misleading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&#8195;The Company
has been duly incorporated and is an existing corporation in good standing under the laws of the State of Delaware, with corporate power and authority to own its properties and conduct its business as described in the most recent Preliminary
Prospectus and the Prospectus; and the Company is duly </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">
qualified to do business as a foreign corporation in good standing in all other jurisdictions in which its ownership or lease of property or the conduct of its business requires such
qualification, except where the failure to be so qualified or be in good standing would not, individually or in the aggregate, have a material adverse effect on the financial condition, business, properties, results of operations or affairs of the
Company and its subsidiaries taken as a whole (a &#147;<B>Material Adverse Effect</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j)&#8195;Each subsidiary
of the Company that is material to the Company and its subsidiaries taken as a whole (collectively, the &#147;<B>Significant Subsidiaries</B>&#148;) is listed on <U>Exhibit A</U> hereto, together with its jurisdiction of organization and the
beneficial ownership of the Company therein. Each Significant Subsidiary has been duly organized and is an existing corporation or limited liability company in good standing under the laws of the jurisdiction of its organization, with corporate or
limited liability company power and authority, as the case may be, to own its properties and conduct its business as described in the most recent Preliminary Prospectus and the Prospectus; and each Significant Subsidiary of the Company is duly
qualified to do business as a foreign entity in good standing in all other jurisdictions in which its ownership or lease of property or the conduct of its business requires such qualification, except where the failure to be so qualified or be in
good standing would not have a Material Adverse Effect; all of the issued and outstanding capital stock or membership interests of each Significant Subsidiary of the Company have been duly authorized and validly issued and are fully paid and
nonassessable; and the capital stock or membership interests of each Significant Subsidiary owned by the Company, directly or through subsidiaries, are owned, except to the extent set forth in <U>Exhibit A</U> hereto, free and clear of any mortgage,
pledge, lien, security interest, claim, encumbrance or defect of any kind. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k)&#8195;This Agreement has been duly
authorized, executed and delivered by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l)&#8195;The Indenture has been duly authorized and executed by the
Company and, assuming due authorization, execution and delivery by the Trustee, constitutes a valid and legally binding obligation of the Company, enforceable against the Company in accordance with its terms, except to the extent that enforceability
may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws relating to creditors&#146; rights and remedies generally and by general principles of equity and concepts of reasonableness (regardless of whether
enforcement is sought in a proceeding at law or in equity); and the Indenture conforms in all material respects to the description thereof contained in the most recent Preliminary Prospectus and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m)&#8195;The Notes have been duly authorized by the Company, and when executed, authenticated and delivered and paid for as
provided in this Agreement and the Indenture, the Notes will have been duly executed, authenticated, issued and delivered and will constitute valid and legally binding obligations of the Company entitled to the benefits of the Indenture and
enforceable against the Company in accordance with their terms, except to the extent that enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws relating to creditors&#146; rights and remedies
generally and by general principles of equity and concepts of reasonableness (regardless of whether enforcement is sought in a proceeding at law or in equity); and the Notes conform in all material respects to the description thereof contained in
the Disclosure Package and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n)&#8195;The execution, delivery and performance of the Indenture and this
Agreement and the issuance and sale of the Notes will not require the consent, approval, authorization or order of, or filing with, any governmental agency or body or any court (except such as have been obtained or made and such as may be required
under state securities laws). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o)&#8195;The execution, delivery and performance of the Indenture and this Agreement and
the issuance and sale of the Notes and compliance with the terms and provisions thereof will not conflict with or result in a breach or violation of any of the terms and provisions of, and do not and will not constitute a default (or an event that,
but for the giving of notice or the lapse of time or both, would constitute an event of default) under, or result in the creation or imposition of any lien, charge or encumbrance upon any material assets or properties of the Company or any of its
subsidiaries under (i)&nbsp;the charter, <FONT STYLE="white-space:nowrap">by-laws</FONT> or other organizational documents of the Company or any Significant Subsidiary, (ii)&nbsp;any statute, rule, regulation, order or decree of any governmental or
regulatory agency or body or any court, domestic or foreign, having jurisdiction over the Company or any subsidiary or any of their properties, assets or operations or (iii)&nbsp;any indenture, mortgage, loan or credit agreement, note, lease,
permit, license or other agreement or instrument to which the Company or any subsidiary is a party or by which the Company or any subsidiary is bound or to which any of the properties, assets or operations of the Company or any subsidiary is
subject, except, in the case of clauses (ii)&nbsp;and (iii), for such breaches or violations which would not, individually or in the aggregate, have a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p)&#8195;The Company and its subsidiaries have good and marketable title to
all real properties owned by them, in each case free and clear of any mortgage, pledge, lien, security interest, claim or other encumbrance or defect; the Company and its subsidiaries hold any leased real property under valid, subsisting and
enforceable leases or subleases with no exceptions that would materially interfere with the use made or to be made thereof by them; neither the Company nor any of its subsidiaries is in material default under any such lease or sublease; and no
material claim of any sort has been asserted by anyone adverse to the rights of the Company or any subsidiary under any such lease or sublease or affecting or questioning the right of such entity to the continued possession of the leased or
subleased properties under any such lease or sublease, except in each case as would not, individually or in the aggregate, have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q)&#8195;Except as described in the most recent Preliminary Prospectus and the Prospectus, the Company and its subsidiaries
possess adequate certificates, authorizations, licenses or permits issued by appropriate governmental agencies or bodies necessary to conduct the business now operated by them, except as would not, individually or in the aggregate, have a Material
Adverse Effect, and have not received any notice of proceedings relating to the revocation or modification of any such certificate, authorization, license or permit that, individually or in the aggregate, could have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r)&#8195;The Company and each of its subsidiaries have filed all tax returns required to be filed, which returns are complete
and correct in all material respects, and neither the Company nor any of its subsidiaries is in default in the payment of any taxes which were payable pursuant to said returns or any assessments with respect thereto, in each case except as would
not, individually or in the aggregate, have a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s)&#8195;Neither the filing of the Registration
Statement, the most recent Preliminary Prospectus or the Prospectus nor the offer or sale of the Notes as contemplated by this Agreement gives rise to any rights, other than those which have been duly waived or satisfied, for or relating to the
registration of any securities of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t)&#8195;Except as described in the most recent Preliminary Prospectus
and the Prospectus, (i)&nbsp;neither the Company nor any of its Significant Subsidiaries is in violation of its charter or <FONT STYLE="white-space:nowrap">by-laws</FONT> or other organizational documents, (ii)&nbsp;neither the Company nor any of
its subsidiaries is in violation of any applicable law, ordinance, administrative or governmental rule or regulation, or any order, decree or judgment of any court or governmental agency or body having jurisdiction over the Company or any of its
subsidiaries and (iii)&nbsp;no event of default or event that, but for the giving of notice or the lapse of time or both, would constitute an event of default, exists, or as a result of the consummation of the sale of the Notes will exist, under any
indenture, mortgage, loan agreement, note, lease, permit, license or other agreement or instrument to which the Company or any of its subsidiaries is a party or to which any of the properties, assets or operations of the Company or any such
subsidiary is subject, except, in the case of clauses (ii)&nbsp;and (iii), for such violations and defaults that would not, individually or in the aggregate, have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u)&#8195;Except as described in the most recent Preliminary Prospectus and the Prospectus, there are no pending actions,
suits or proceedings against or, to the knowledge of the Company, affecting the Company, any of its subsidiaries or any of their respective properties, assets or operations that would have, individually or in the aggregate, a Material Adverse
Effect, or could materially and adversely affect the ability of the Company to perform its obligations under this Agreement, the Indenture or any other document governing the sale of the Notes; and no such actions, suits or proceedings are, to the
knowledge of the Company, threatened. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v)&#8195;The financial statements of the Company and its consolidated
subsidiaries, together with the related schedules, if any, and notes included or incorporated by reference in the most recent Preliminary Prospectus and the Prospectus, present fairly, in all material respects, the respective financial position of
the Company and its consolidated subsidiaries as of the dates shown and their results of operations and cash flows for the periods shown, and have been prepared in conformity with generally accepted accounting principles in the United States applied
on a consistent basis, except as disclosed therein. The other financial and statistical information set forth in the most recent Preliminary Prospectus and the Prospectus present fairly, in all material respects, the information shown therein and
have been, except as disclosed therein, compiled on a basis consistent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">
with that of the financial statements included or incorporated by reference in the most recent Preliminary Prospectus and the Prospectus. The interactive data in eXtensible Business Reporting
Language incorporated by reference in the most recent Preliminary Prospectus and the Prospectus has been prepared in accordance with the Commission&#146;s rules and guidelines applicable thereto (as of the dates such interactive data were filed) in
all material respects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w)&#8195;Since the date of the latest audited financial statements of the Company included or
incorporated by reference in the most recent Preliminary Prospectus and the Prospectus, there has been no material adverse change, nor any development or event expected to result in a prospective material adverse change, in the financial condition,
business, properties or results of operations of the Company and its subsidiaries taken as a whole, other than those set forth in or contemplated by the most recent Preliminary Prospectus and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x)&#8195;There is no contract or document required to be described in the Registration Statement, the most recent Preliminary
Prospectus or the Prospectus or to be filed as an exhibit to the Registration Statement or to a document incorporated by reference into the Registration Statement, the most recent Preliminary Prospectus or the Prospectus which is not described or
filed as required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y)&#8195;The Company is not and, after giving effect to the offering and sale of the Notes and the
application of the proceeds thereof as described in the most recent Preliminary Prospectus and the Prospectus, will not be required to register as, an &#147;investment company&#148; as defined in the Investment Company Act of 1940, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z)&#8195;The Company and its Significant Subsidiaries maintain a system of internal accounting controls over financial
reporting. The Company&#146;s internal control over financial reporting include those policies and procedures that pertain to the Company&#146;s ability to record, process, summarize and report a system of internal accounting controls and procedures
to provide reasonable assurance, at an appropriate cost/benefit relationship, that the unauthorized acquisition, use or disposition of assets are prevented or timely detected and that transactions are authorized, recorded and reported properly to
permit the preparation of financial statements in accordance with generally accepted accounting principles in the United States and receipts and expenditures are duly authorized. The Company&#146;s internal control over financial reporting were
effective and provided such reasonable assurance for the preparation of financial statements as of December&nbsp;31, 2023, and there has been no change in the Company&#146;s internal control over financial reporting subsequent to December&nbsp;31,
2023 that has materially affected, or is reasonably likely to materially affect, the Company&#146;s internal control over financial reporting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa)&#8195;The Company has made the evaluations of the Company&#146;s disclosure controls and procedures required under Rule <FONT
STYLE="white-space:nowrap">13a-15(b)</FONT> under the Exchange Act and management&#146;s conclusions regarding the effectiveness of such disclosure controls and procedures were included in the Company&#146;s annual report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb)&#8195;Neither the Company
nor any of its subsidiaries nor, to the Company&#146;s knowledge, any director, officer, agent, employee or affiliate of the Company or any of its subsidiaries is aware of or has taken any action (with respect to any agent or affiliate, while acting
on behalf of the Company or any of its subsidiaries), directly or indirectly, that would result in a violation by such persons of the FCPA, including, without limitation, making use of the mails or any means or instrumentality of interstate commerce
corruptly in furtherance of an offer, payment, promise to pay or authorization of the payment of any money, or other property, gift, promise to give, or authorization of the giving of anything of value to any &#147;foreign official&#148; (as such
term is defined in the FCPA) or any foreign political party or official thereof or any candidate for foreign political office, in contravention of the FCPA, and the Company, its subsidiaries and, to the Company&#146;s knowledge, its affiliates, have
conducted their businesses in compliance in all material respects with the FCPA and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>FCPA</B>&#148; means Foreign Corrupt Practices Act of 1977, as amended, and the
rules&nbsp;and regulations thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc)&#8195;The operations of the Company and its subsidiaries are and have been
conducted at all times in compliance in all material respects with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all
applicable jurisdictions, the rules&nbsp;and regulations thereunder and any related or similar rules, regulations or guidelines issued, administered or enforced by any governmental agency (collectively, the &#147;<B>Money Laundering Laws</B>&#148;)
and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the Company&#146;s
knowledge, threatened. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd)&#8195;Neither the Company nor any of its subsidiaries nor, to the Company&#146;s knowledge,
any director, officer, agent, employee or affiliate of the Company or any of its subsidiaries is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department (&#147;<B>OFAC</B>&#148;);
and the Company will not directly or indirectly use the net proceeds from the sale of the Notes, or lend, contribute or otherwise make available such proceeds, to any subsidiary, joint venture partner or other person or entity, for the purpose of
financing the activities of any person currently subject to any U.S. sanctions administered by OFAC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee)&#8195;<I>Cybersecurity; Data Protection.</I> Except as would not, individually or in the aggregate, have a Material
Adverse Effect: (i)&nbsp;the Company and its subsidiaries&#146; information technology assets and equipment, computers, systems, networks, hardware, software, websites and applications (collectively, &#147;<B>IT Systems</B>&#148;) are, to the
Company&#146;s knowledge, free and clear of all bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants; (ii)&nbsp;the Company and its subsidiaries have implemented and maintain commercially reasonable controls, policies,
procedures, and safeguards (including administrative, technical, an physical safeguards) to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and data
(including all personal, personally identifiable, sensitive, confidential or regulated data (&#147;<B>Personal Data</B>&#148;)) used in connection with their businesses; and (iii)&nbsp;there have been no breaches, violations, outages or unauthorized
uses of, acquisitions of, disclosures of or accesses to same, except for those that have been remedied without material cost or liability or the duty to notify any other person, nor are there any incidents currently under internal review or pending
investigations relating to the same. The Company and its subsidiaries are presently in material compliance with all applicable laws, statutes and judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory
authority relating to the privacy and security of IT Systems and Personal Data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">For purposes of this Section&nbsp;1, as well as for
Section&nbsp;6 hereof, references to &#147;<B>the most recent Preliminary Prospectus and the Prospectus</B>&#148; or &#147;<B>the Disclosure Package and the Prospectus</B>&#148; are to each of the most recent Preliminary Prospectus or the Disclosure
Package, as the case may be, and the Prospectus as separate or stand-alone documentation (and not the most recent Preliminary Prospectus or the Disclosure Package, as the case may be, and the Prospectus taken together), so that representations,
warranties, agreements, conditions and legal opinions will be made, given or measured independently in respect of each of the most recent Preliminary Prospectus or the Disclosure Package, as the case may be, and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.&#8195;<I>Purchase of the Notes by the Underwriters</I>. Subject to the terms and conditions and upon the basis of the representations and
warranties herein set forth, the Company agrees to issue and sell to the Underwriters, and each of the Underwriters agrees, severally and not jointly, to purchase from the Company, at a price equal to (i)&nbsp;in the case of the Series A Junior
Subordinated Notes, 99.000% of the principal amount of the Series A Junior Subordinated Notes and (ii)&nbsp;in the case of the Series B Junior Subordinated Notes, 99.000% of the principal amount of the Series B Junior Subordinated Notes plus, in
each case, accrued interest, if any, from December&nbsp;10, 2024 to, but excluding, the Closing Date with respect to each of the applicable series of Notes, the respective principal amount of the Notes set forth opposite such Underwriter&#146;s name
in <U>Schedule I</U> hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.&#8195;<I>Delivery of and Payment for the Notes</I>. Delivery of the Notes will be made at the offices of
Simpson Thacher&nbsp;&amp; Bartlett LLP, 425 Lexington Avenue, New York, NY 10017, or at such place or places as mutually may be agreed upon by the Company and the Underwriters, at 9:00 A.M., New York City time, on December&nbsp;10, 2024 or on such
later date not more than seven Business Days after such date as may be determined by the Representatives and the Company (the &#147;<B>Closing Date</B>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Delivery of the Notes will be made to the Representatives by or on behalf of the Company
against payment of the purchase price therefor by wire transfer of immediately available funds. Delivery of the Notes will be made through the facilities of The Depository Trust Company unless the Representatives will otherwise instruct. Delivery of
the Notes at the time and place specified in this Agreement is a further condition to the obligations of each Underwriter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.&#8195;<I>Covenants of the Company</I>. The Company covenants and agrees with each Underwriter that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;The Company (i)&nbsp;will prepare the Prospectus in a form approved by the Representatives and file the Prospectus
pursuant to Rule 424(b) of the Rules and Regulations within the time period prescribed by such Rule; (ii)&nbsp;will not file any amendment or supplement to the Registration Statement or the Prospectus or file any document under the Exchange Act
(except for filings of annual reports on Form 10-K and quarterly reports on Form 10-Q under the Exchange Act) before the termination of the offering of the Notes by the Underwriters if such document would be deemed to be incorporated by reference
into the Prospectus, which filing is not consented to by the Representatives after reasonable notice thereof (such consent not to be unreasonably withheld or delayed); (iii) will advise the Representatives, promptly after it receives notice thereof,
of the time when any amendment or supplement to the Registration Statement, the most recent Preliminary Prospectus or the Prospectus has been filed and will furnish the Representatives with copies thereof; (iv)&nbsp;will prepare the Final Term
Sheet, substantially in the form of <U>Schedule III</U> hereto and approved by the Representatives and file the Final Term Sheet pursuant to Rule 433(d) of the Rules and Regulations within the time period prescribed by such Rule; (v)&nbsp;will
advise the Representatives promptly after it receives notice thereof, of the issuance by the Commission or any state or other regulatory body of any stop order or any order suspending the effectiveness of the Registration Statement, suspending or
preventing the use of any Preliminary Prospectus, the Prospectus or any Issuer Free Writing Prospectus or suspending the qualification of the Notes for offering or sale in any jurisdiction, of the initiation or threatening of any proceedings for any
such purpose or pursuant to Section&nbsp;8A of the Securities Act, of receipt by the Company from the Commission of any notice of objection to the use of the Registration Statement or any post-effective amendment thereto or of any request by the
Commission for the amending or supplementing of the Registration Statement, the Prospectus or any Issuer Free Writing Prospectus or for additional information; and (vi)&nbsp;will use its reasonable best efforts to prevent the issuance of any stop
order or other such order or any such notice of objection and, if a stop order or other such order is issued or any such notice of objection is received, to obtain as soon as possible the lifting or withdrawal thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;The Company will furnish to each of the Underwriters and to counsel for the Underwriters such number of conformed
copies of the Registration Statement, as originally filed and each amendment thereto (excluding exhibits other than this Agreement), any Preliminary Prospectus, the Final Term Sheet and any other Issuer Free Writing Prospectus, the Prospectus and
all amendments and supplements to any of such documents (including any document filed under the Exchange Act and deemed to be incorporated by reference in the Registration Statement, any Preliminary Prospectus or the Prospectus), in each case as
soon as available and in such quantities as the Representatives may from time to time reasonably request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;During the period in which the Prospectus relating to the Notes (or in lieu thereof, the notice referred to in Rule
173(a) of the Rules and Regulations) is required to be delivered under the Securities Act, the Company will comply with all requirements imposed upon it by the Securities Act and by the Rules and Regulations, as from time to time in force, so far as
is necessary to permit the continuance of sales of or dealings in the Notes as contemplated by the provisions of this Agreement and by the Prospectus. If during such period any event occurs as a result of which the Prospectus as then amended or
supplemented would include an untrue statement of a material fact or omit to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, or if during such period it
is necessary to amend the Registration Statement or amend or supplement the Prospectus or file any document to comply with the Securities Act, the Company will promptly notify the Representatives and will, subject to Section&nbsp;4(a) hereof, amend
the Registration Statement, or amend or supplement the Prospectus, as the case may be, or file any document (in each case, at the expense of the Company) so as to correct such statement or omission or to effect such compliance, and will furnish
without charge to each Underwriter as many written and electronic copies of any such amendment or supplement as the Representatives may from time to time reasonably request. Neither the Representatives&#146; consent to nor their delivery to offerees
or investors of, any such amendment or supplement shall constitute a waiver of any of the conditions set forth in Section&nbsp;6 of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#8195;As soon as practicable, the Company will make generally available
to its security holders and the Underwriters an earnings statement satisfying the requirements of Section&nbsp;11(a) of the Securities Act and Rule 158 of the Rules and Regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&#8195;The Company agrees, whether or not this Agreement becomes effective or is terminated or the sale of the Notes to the
Underwriters is consummated, to pay all fees, expenses, costs and charges in connection with: (i)&nbsp;the preparation, printing, filing, registration, delivery and shipping of the Registration Statement (including any exhibits thereto), any
Preliminary Prospectus, any Issuer Free Writing Prospectus, the Prospectus and any amendments or supplements thereto; (ii)&nbsp;the printing, producing, copying and delivering of this Agreement, the Indenture, closing documents (including any
compilations thereof) and any other agreements, memoranda, correspondence and other documents printed and delivered in connection with the offering, purchase, sale and delivery of the Notes; (iii)&nbsp;the services of the Company&#146;s independent
registered public accounting firm; (iv)&nbsp;the services of the Company&#146;s counsel; (v)&nbsp;the qualification of the Notes under the securities laws of the several jurisdictions as provided in Section&nbsp;4(i) hereof; (vi)&nbsp;any rating of
the Notes by rating agencies; (vii)&nbsp;the services of the Trustee and any agent of the Trustee (including the fees and disbursements of counsel for the Trustee); (viii) any &#147;road show&#148; or other investor presentations relating to the
offering of the Notes (including, without limitation, for meetings and travel); and (ix)&nbsp;the performance of its otherwise incident obligations hereunder for which provision is not otherwise made in this Section&nbsp;4(e). It is understood,
however, that, except as provided in this Section&nbsp;4(e) or Sections 7 and 9 hereof, the Underwriters will pay all of their own costs and expenses, including the fees and expenses of counsel to the Underwriters and any advertising expenses
incurred in connection with the offering of the Notes. If the sale of the Notes provided for herein is not consummated by reason of acts of the Company or changes in circumstances of the Company pursuant to Section&nbsp;9 of this Agreement which
prevent this Agreement from becoming effective, or by reason of any failure, refusal or inability on the part of the Company to perform any agreement on its part to be performed or because any other condition of the Underwriters&#146; obligations
hereunder is not fulfilled or if the Underwriters decline to purchase the Notes for any reason permitted under this Agreement (other than by reason of a default by any of the Underwriters pursuant to Section&nbsp;8 or if the Underwriters terminate
this Agreement under Section&nbsp;9 of this Agreement upon the occurrence of any event specified in clause (iii), (iv), (vi), (vii) or (viii)&nbsp;of Section&nbsp;6(d)), the Company will reimburse the Underwriters for all reasonable <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> disbursements (including fees and expenses of counsel to the Underwriters) incurred by the Underwriters in connection with any investigation or preparation made
by them in respect of the marketing of the Notes or in contemplation of the performance by them of their obligations hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&#8195;Until termination of the offering of the Notes, the Company will timely file all reports, documents and amendments
to previously filed documents required to be filed by it pursuant to Section&nbsp;12, 13(a), 13(c), 14 or 15(d) of the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&#8195;The Company will apply the net proceeds from the sale of the Notes as set forth in the most recent Preliminary
Prospectus and the Prospectus under the caption &#147;Use of Proceeds.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&#8195;The Company will pay the required
Commission filing fees relating to the Notes within the time period required by Rule 456(b)(1) of the Rules and Regulations without regard to the proviso therein and otherwise in accordance with Rules 456(b) and 457(r) of the Rules and Regulations.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&#8195;The Company will use reasonable best efforts to arrange for the qualification of the Notes and the
determination of their eligibility for investment under the blue sky laws of such jurisdictions as the Representatives designate and will continue such qualifications in effect so long as required for the distribution of the Notes by the
Underwriters, provided that the Company will not be required to qualify as a foreign corporation or to file a general consent to service of process or subject itself to taxation in any such jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.&#8195;<I>Free Writing Prospectuses</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;The Company represents and warrants to, and agrees with, each Underwriter that (i)&nbsp;the Company has not made,
and will not make, any offer relating to the Notes that would constitute an Issuer Free Writing Prospectus without the prior consent of the Representatives (which consent being deemed to have been given with respect to (A)&nbsp;the Final Term Sheet
prepared and filed pursuant to Section&nbsp;4(a) hereof and (B)&nbsp;any other Issuer Free Writing Prospectus identified on <U>Schedule II</U> hereto); (ii) each Issuer Free Writing Prospectus conformed or will conform in all material respects to
the requirements of the Securities Act and the Rules and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">
Regulations on the date of first use, and the Company has complied with any filing requirements applicable to such Issuer Free Writing Prospectus pursuant to Rule 433 of the Rules and
Regulations; (iii)&nbsp;each Issuer Free Writing Prospectus will not, as of its issue date and through the time the Notes are delivered pursuant to Section&nbsp;3 hereof, include any information that conflicts with the information contained in the
Registration Statement, the most recent Preliminary Prospectus and the Prospectus; and (iv)&nbsp;each Issuer Free Writing Prospectus, when considered together with the information contained in the most recent Preliminary Prospectus, did not, as of
the Applicable Time, does not, as of the date hereof, and will not, as of the Closing Date, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein,
in the light of the circumstances under which they were made, not misleading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;Each Underwriter represents and
warrants to, and agrees with, the Company and each other Underwriter that it has not made, and will not make any offer relating to the Notes that would constitute a &#147;free writing prospectus&#148; (as defined in Rule&nbsp;405 of the Rules and
Regulations) required to be filed with the Commission, without the prior consent of the Company and the Representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;The Company agrees that if at any time following issuance of an Issuer Free Writing Prospectus any event occurred or
occurs as a result of which such Issuer Free Writing Prospectus would conflict with the information in the Registration Statement, the most recent Preliminary Prospectus or the Prospectus or would include any untrue statement of a material fact or
omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances then prevailing, not misleading, the Company will give prompt notice thereof to the Representatives and, if requested by the
Representatives, will prepare and furnish without charge to each Underwriter an Issuer Free Writing Prospectus or other document which will correct such conflict, statement or omission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.&#8195;<I>Conditions of Underwriters</I><I>&#146;</I><I> Obligations</I>. The obligations of the Underwriters hereunder are subject to the
accuracy, as of the date hereof and the Closing Date (as if made at the Closing Date), of the representations and warranties of the Company contained herein, to the performance by the Company of its obligations hereunder and to the following
additional conditions: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;The Prospectus shall have been filed with the Commission in a timely fashion in
accordance with Section&nbsp;4(a) hereof; all filings (including, without limitation, the Final Term Sheet) required by Rule 424(b) or Rule 433 of the Rules and Regulations shall have been made within the time periods prescribed by such Rules, and
no such filings will have been made without the consent of the Representatives (such consent not to be unreasonably withheld or delayed); no stop order suspending the effectiveness of the Registration Statement or any amendment or supplement
thereto, preventing or suspending the use of any Preliminary Prospectus, any Issuer Free Writing Prospectus or the Prospectus, or suspending the qualification of the Notes for offering or sale in any jurisdiction shall have been issued; no
proceedings for the issuance of any such order shall have been initiated or threatened pursuant to Section&nbsp;8A of the Securities Act; no notice of objection of the Commission to use of the Registration Statement or any post-effective amendment
thereto shall have been received by the Company; and any request of the Commission for additional information (to be included in the Registration Statement or the Prospectus or otherwise) shall have been disclosed to the Representatives and complied
with to the Representatives&#146; reasonable satisfaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;The Representatives shall have received a letter,
dated the date of this Agreement, from Ernst&nbsp;&amp; Young LLP (&#147;<B>E&amp;Y</B>&#148;) addressed to the Underwriters, confirming that they are the independent public accountants with respect to the Company, within the meaning of the
Securities Act and the applicable published rules and regulations thereunder and to the effect that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&#8195;in their
opinion the financial statements and schedules of the Company, if any, examined by them and included or incorporated by reference in the most recent Preliminary Prospectus or the Prospectus, comply as to form in all material respects with the
applicable accounting requirements of the Securities Act and the Exchange Act and the related rules and regulations adopted by the Commission; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&#8195;on the basis of a reading of the latest available interim financial statements of the Company, inquiries of
officials of the Company, who have responsibility for financial and accounting matters and other specified procedures, nothing came to their attention that caused them to believe that: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the date of the latest available balance sheet read by such accountants, and at a subsequent specified date
not more than three Business Days prior to the date of this Agreement, there was any change in the common stock, increase in long-term debt or decrease in consolidated net current assets or shareholders&#146; equity of the Company, as compared with
amounts shown on the latest balance sheet included or incorporated by reference in the most recent Preliminary Prospectus or the Prospectus; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for the period from the closing date of the latest income statement included or incorporated by reference in
the most recent Preliminary Prospectus or the Prospectus to the closing date of the latest available income statement read by such accountants and to a subsequent specified date not more than three Business Days prior to the date of this Agreement,
there were any decreases, as compared with the corresponding period in the preceding year, in consolidated net revenues or in the total or <FONT STYLE="white-space:nowrap">per-share</FONT> amounts of consolidated income from continuing operations or
of consolidated net income of the Company, or any increases or decreases, as the case may be, in other items specified by the Representatives; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">except in all cases set forth in clauses (A)&nbsp;and (B) above for changes, increases or decreases which the
most recent Preliminary Prospectus or the Prospectus discloses have occurred or may occur or which are described in such letter; and </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&#8195;they have compared specified dollar amounts (or percentages derived from such dollar amounts), numerical data and
other financial information contained in the most recent Preliminary Prospectus or the Prospectus (in each case to the extent that such dollar amounts, percentages, numerical data and other financial information are derived from the general
accounting records of the Company and its subsidiaries, subject to the internal controls of the Company&#146;s accounting system, or are derived directly from such records by analysis or computation) with the results obtained from inquiries, a
reading of such general accounting records and other procedures specified in such letter and have found such dollar amounts, percentages, numerical data and other financial information to be in agreement with such results except as otherwise
specified in such letter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;The Representatives shall have received a letter, addressed to the Underwriters,
dated the Closing Date, from E&amp;Y, which meets the requirements of subsection (b)&nbsp;of this Section, except that the specified date referred to in such subsection will be a date not more than three days prior to the Closing Date for the
purposes of this subsection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#8195;Subsequent to the execution and delivery of this Agreement, there shall not have
occurred (i)&nbsp;any change, or any development involving a prospective change, in the condition (financial or other), business, properties or results of operations of the Company and its subsidiaries, taken as a whole, which, in the judgment of
the Representatives, is material and adverse and makes it impractical or inadvisable to proceed with completion of the offering or the sale of and payment for the Notes; (ii)&nbsp;any downgrading in the rating of any debt securities of the Company
by any &#147;nationally recognized statistical rating organization&#148; (as defined for purposes of Section&nbsp;3(a)(62) of the Exchange Act), or any public announcement that any such organization has under surveillance or review its rating of any
debt securities of the Company (other than an announcement with positive implications of a possible upgrading, and no implication of a possible downgrading, of such rating); (iii)&nbsp;any change in U.S. or international financial, political or
economic conditions or currency exchange rates or exchange controls as would, in the judgment of the Representatives, be likely to prejudice materially the success of the proposed issue, sale or distribution of the Notes, whether in the primary
market or in respect of dealings in the secondary market; (iv)&nbsp;any material suspension or material limitation of trading in securities generally on the New York Stock Exchange or any setting of minimum prices for trading on such exchange;
(v)&nbsp;any suspension of trading of any securities of the Company on any exchange or in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market; (vi)&nbsp;any banking moratorium declared by U.S.
Federal or New York authorities; (vii)&nbsp;any major disruption of settlements of securities or clearance services in the United States; or (viii)&nbsp;any attack on the United States, outbreak or escalation of major hostilities or act of terrorism
involving the United States, any declaration of war by Congress or any other substantial national or international calamity or emergency if, in the judgment of the Representatives, the effect of any such attack, outbreak, escalation, act,
declaration, calamity or emergency makes it impractical or inadvisable to proceed with completion of the offering or sale of and payment for the Notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&#8195;The Representatives shall have received from Wachtell, Lipton,
Rosen&nbsp;&amp; Katz, counsel for the Company, an opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> letter, addressed to the Underwriters, dated the Closing Date substantially to the effect set forth in <U>Exhibits B</U> and <U>C</U>
hereto, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&#8195;The Representatives shall have received from Thomas S. Moffatt, Vice President, Assistant
Secretary and Senior Legal Counsel - Corporate Services of the Company, an opinion, addressed to the Underwriters, dated the Closing Date substantially in the form of <U>Exhibit D</U> hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&#8195;The Representatives shall have received from Simpson Thacher&nbsp;&amp; Bartlett LLP, counsel to the Underwriters,
such opinion or opinions, addressed to the Underwriters, dated the Closing Date and in form and substance satisfactory to the Representatives, with respect to the Notes, Indenture, Registration Statement, Prospectus and Disclosure Package and other
related matters as the Representatives may reasonably require, and the Company shall have furnished to such counsel such documents as they may reasonably request for the purpose of enabling them to pass upon such matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&#8195;The Representatives shall have received a certificate, dated the Closing Date, of the President or any Vice
President and the principal financial or accounting officer of the Company in which such officers, to the best of their knowledge after reasonable investigation, shall state that (i)&nbsp;the representations and warranties of the Company in this
Agreement are true and correct, (ii)&nbsp;the Company has complied with all the agreements and satisfied all the conditions on its part to be performed or satisfied hereunder at or prior to the Closing Date, (iii)&nbsp;no stop order suspending the
effectiveness of the Registration Statement has been issued, no proceedings for any such purpose have been initiated or threatened and (iv)&nbsp;subsequent to the dates of the most recent financial statements in the most recent Preliminary
Prospectus and the Prospectus, there has been no material adverse change, nor any development or event involving a prospective material adverse change, in the financial condition, business, properties or results of operations of the Company and its
subsidiaries, taken as a whole, other than those set forth in or contemplated by the most recent Preliminary Prospectus and the Prospectus or as described in such certificate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will furnish the Underwriters with such conformed copies of such opinions, certificates, letters and documents as the Underwriters
reasonably request. The Representatives may in their sole discretion waive on behalf of the Underwriters compliance with any conditions to the obligations of the Underwriters hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.&#8195;<I>Indemnification and Contribution</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;The Company will indemnify and hold harmless each Underwriter, its partners, members, directors and officers and
affiliates and each person, if any, who controls such Underwriter within the meaning of Section&nbsp;15 of the Securities Act, from and against any loss, claim, damage or liability (or any action in respect thereof), joint or several, to which such
Underwriter or such person may become subject, under the Securities Act or otherwise, insofar as such loss, claim, damage or liability (or action in respect thereof) arises out of or is based upon (i)&nbsp;any untrue statement or alleged untrue
statement of a material fact contained in the Registration Statement, any Preliminary Prospectus, the Prospectus, or the Disclosure Package, each as amended or supplemented, any Issuer Free Writing Prospectus or any &#147;issuer information&#148;
filed or required to be filed pursuant to Rule&nbsp;433(d) of the Rules and Regulations or (ii)&nbsp;the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein (in the
case of any Preliminary Prospectus, Issuer Free Writing Prospectus, the Prospectus and the Disclosure Package, in the light of the circumstances under which they were made) not misleading, and will reimburse each Underwriter for any legal or other
expenses as reasonably incurred by such Underwriter in connection with investigating, preparing to defend or defending against or appearing as a third-party witness in connection with any such loss, claim, damage, liability or action,
notwithstanding the possibility that payments for such expenses might later be held to be improper, in which case such payments will be promptly refunded; <I>provided</I>, <I>however</I>, that the Company will not be liable under this
Section&nbsp;7(a) in any such case to the extent that any such loss, claim, damage, liability or action arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in
conformity with written information furnished to the Company by any Underwriter through the Representatives specifically for use therein (which information is specified in Section&nbsp;12 hereof). The
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">
foregoing indemnity agreement shall not inure to the benefit of any Underwriter if (i)&nbsp;such loss, claim, damage or liability (or action in respect thereof) arises out of or is based upon an
untrue statement or alleged untrue statement or omission or alleged omission made in any Preliminary Prospectus, (ii)&nbsp;the Company informed the Representatives of such untrue statement or alleged untrue statement or omission or alleged omission
prior to the Applicable Time, (iii)&nbsp;such untrue statement or alleged untrue statement or omission or alleged omission was corrected in an amended or supplemented Preliminary Prospectus (or, where permitted by law, an Issuer Free Writing
Prospectus) and such corrected Preliminary Prospectus (or Issuer Free Writing Prospectus) was provided to the Underwriters such that the Underwriters had a reasonably sufficient amount of time prior to the Applicable Time to deliver such corrected
Preliminary Prospectus (or Issuer Free Writing Prospectus) to the persons to whom the Underwriters are selling the Notes, (iv)&nbsp;the timely delivery of such corrected Preliminary Prospectus (or Issuer Free Writing Prospectus) to such person prior
to the Applicable Time would have constituted a complete defense to the losses, claims, damages and liabilities asserted by such person and (v)&nbsp;such corrected Preliminary Prospectus (or Issuer Free Writing Prospectus) was not sent or given by
or on behalf of such Underwriter to such person prior to the Applicable Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;Each Underwriter severally, but
not jointly, will indemnify and hold harmless the Company, its directors, officers and affiliates and each person, if any, who controls the Company within the meaning of Section&nbsp;15 of the Securities Act against any loss, claim, damage or
liability (or any action in respect thereof) to which the Company or such person may become subject, under the Securities Act or otherwise, insofar as such loss, claim, damage or liability (or action in respect thereof) arises out of or is based
upon (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, any Preliminary Prospectus, the Prospectus, the Disclosure Package, each as amended or supplemented, or any Issuer Free
Writing Prospectus or (ii)&nbsp;the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein (in the case of any Preliminary Prospectus, Issuer Free Writing Prospectus,
the Prospectus and the Disclosure Package, in the light of the circumstances under which they were made) not misleading, and will reimburse the Company for any legal or other expenses reasonably incurred by the Company in connection with
investigating, preparing to defend or defending against or appearing as a third-party witness in connection with any such loss, claim, damage, liability or action notwithstanding the possibility that payments for such expenses might later be held to
be improper, in which case such payments will be promptly refunded; <I>provided</I>, <I>however</I>, that such indemnification or reimbursement will be available in each such case to the extent, but only to the extent, that such untrue statement or
alleged untrue statement or omission or alleged omission was made in reliance upon and in conformity with written information furnished to the Company by such Underwriter through the Representatives, specifically for use therein (which information
is specified in Section&nbsp;12 hereof). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;Promptly after receipt by an indemnified party under this Section of
notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against an indemnifying party under subsection (a)&nbsp;or (b) above, notify the indemnifying party of the commencement thereof; but
the failure to notify the indemnifying party shall not relieve it from any liability that it may have under subsection (a)&nbsp;or (b) above, except to the extent that it has been materially prejudiced (through the forfeiture of substantive rights
or defenses) by such failure; and provided further that the failure to notify the indemnifying party shall not relieve it from any liability that it may have to an indemnified party otherwise than under subsection (a)&nbsp;or (b) above. In case any
such action is brought against any indemnified party and it notifies an indemnifying party of the commencement thereof, the indemnifying party will be entitled to participate therein and, to the extent that it may wish, jointly with any other
indemnifying party similarly notified, to assume the defense thereof, with counsel satisfactory to such indemnified party (who shall not, except with the consent of the indemnified party, be counsel to the indemnifying party), and after notice from
the indemnifying party to such indemnified party of its election to assume the defense thereof, the indemnifying party will not be liable to such indemnified party under this Section for any legal or other expenses subsequently incurred by such
indemnified party in connection with the defense thereof other than reasonable costs of investigation. No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement of any pending or threatened action
in respect of which any indemnified party is or could have been a party and indemnity could have been sought hereunder by such indemnified party unless such settlement (i)&nbsp;includes an unconditional release of such indemnified party from all
liability on any claims that are the subject matter of such action and (ii)&nbsp;does not include a statement as to or an admission of fault, culpability or a failure to act, by or on behalf of any indemnified party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#8195;If the indemnification provided for in this Section is unavailable
or insufficient to hold harmless an indemnified party under subsection (a)&nbsp;or (b) above, then the indemnifying party shall contribute to the amount paid or payable by such indemnified party as a result of the losses, claims, damages or
liabilities referred to in subsection (a)&nbsp;or (b) above (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received by the Company on the one hand and the Underwriters on the other from the offering of the Notes or
(ii)&nbsp;if the allocation provided by clause (i)&nbsp;above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i)&nbsp;above but also the relative fault of the
Company on the one hand and the Underwriters on the other in connection with the statements or omissions which resulted in such losses, claims, damages or liabilities as well as any other relevant equitable considerations. The relative benefits
received by the Company on the one hand and the Underwriters on the other shall be deemed to be in the same proportion as the total net proceeds from the offering (before deducting expenses) received by the Company bear to the total discounts and
commissions received by the Underwriters from the Company under this Agreement. The relative fault shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged
omission to state a material fact relates to information supplied by the Company or the Underwriters and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such untrue statement or omission. The
amount paid by an indemnified party as a result of the losses, claims, damages or liabilities referred to in the first sentence of this subsection (d)&nbsp;shall be deemed to include any legal or other expenses reasonably incurred by such
indemnified party in connection with investigating or defending any action or claim which is the subject of this subsection (d). Notwithstanding the provisions of this subsection (d), no Underwriter shall be required to contribute any amount in
excess of the amount by which the total price at which the Notes purchased by it were resold exceeds the amount of any damages which such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission
or alleged omission. The Underwriters&#146; obligations in this subsection (d)&nbsp;to contribute are several in proportion to their respective purchase obligations and not joint. No person guilty of fraudulent misrepresentation (within the meaning
of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&#8195;The obligations of the Company under this Section shall be in addition to any liability which the Company may
otherwise have and shall extend, upon the same terms and conditions, to each person, if any, who controls any Underwriter within the meaning of the Securities Act or the Exchange Act; and the obligations of the Underwriters under this Section shall
be in addition to any liability which the Underwriters may otherwise have and shall extend, upon the same terms and conditions, to each director of the Company and to each person, if any, who controls the Company within the meaning of the Securities
Act or the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.&#8195;<I>Substitution of Underwriters</I>. If any Underwriter or Underwriters default in their obligations to
purchase Notes hereunder and the aggregate principal amount of the Notes that such defaulting Underwriter or Underwriters agreed but failed to purchase does not exceed 10% of the total principal amount of the Notes, the Representatives may make
arrangements satisfactory to the Company for the purchase of such Notes by other persons, including any of the Underwriters, but if no such arrangements are made by the Closing Date, the <FONT STYLE="white-space:nowrap">non-defaulting</FONT>
Underwriters shall be obligated severally, in proportion to their respective commitments hereunder, to purchase the Notes that such defaulting Underwriter or Underwriters agreed but failed to purchase. If any Underwriter or Underwriters so default
and the aggregate principal amount of the Notes with respect to which such default or defaults occur exceeds 10% of the total principal amount of the Notes and arrangements satisfactory to the Representatives and the Company for the purchase of such
Notes by other persons are not made within 36 hours after such default, this Agreement will terminate without liability on the part of any <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter or the Company, except as provided in
Section&nbsp;7. As used in this Agreement, the term &#147;Underwriter&#148; includes any person substituted for an Underwriter under this Section. Nothing herein will relieve a defaulting Underwriter from liability for its default. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.&#8195;<I>Termination</I>. Until the Closing Date, this Agreement may be terminated by the Representatives on behalf of the Underwriters by
giving notice as hereinafter provided to the Company if (i)&nbsp;the Company will have failed, refused or been unable, at or prior to the Closing Date, to perform any agreement on its part to be performed hereunder, (ii)&nbsp;any of the events
described in Sections 6(d) of this Agreement, shall have occurred, or (iii)&nbsp;any other condition to the Underwriters&#146; obligations hereunder is not fulfilled. Any termination of this Agreement pursuant to this Section&nbsp;9 will be without
liability on the part of the Company or any Underwriter, except as otherwise provided in Sections&nbsp;4(e) and 7 hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Any notice referred to above may be given at the address specified in Section&nbsp;11 of
this Agreement in writing by mail, facsimile or email. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.&#8195;<I>Survival of Certain Provisions</I>. The agreements contained in
Section&nbsp;7 of this Agreement and the representations, warranties and agreements of the Company contained in Sections&nbsp;1 and 4 of this Agreement will survive the delivery of the Notes to the Underwriters hereunder and will remain in full
force and effect, regardless of any termination or cancellation of this Agreement or any investigation made by or on behalf of any indemnified party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.&#8195;<I>Notices</I>. Except as otherwise provided in the Agreement, (a)&nbsp;whenever notice is required by the provisions of this
Agreement to be given to the Company, such notice will be in writing by mail or facsimile transmission addressed to the Company at One CVS Drive, Woonsocket, Rhode Island 02895, facsimile number (401)
<FONT STYLE="white-space:nowrap">765-7887,</FONT> Attention: General Counsel, and (b)&nbsp;whenever notice is required by the provisions of this Agreement to be given to the several Underwriters, such notice will be in writing by mail, email or
facsimile transmission addressed to the Representatives in care of Barclays Capital Inc., 745 Seventh Ave, New York, New York 10019, facsimile number: (646) <FONT STYLE="white-space:nowrap">834-8133,</FONT> Attention: Syndicate Registration,
Citigroup Global Markets Inc., 388 Greenwich Street, New York, New York 10013 and Goldman Sachs&nbsp;&amp; Co. LLC, 200 West Street, New York, New York, 10282. The Company shall be entitled to act and rely upon any request, consent, notice or
agreement given or made on behalf of the Underwriters by the Representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.&#8195;<I>Information Furnished by Underwriters</I>. The
Underwriters severally confirm that the names of each of the Underwriters under the caption &#147;Underwriting&#148; in the most recent Preliminary Prospectus and the Prospectus, the concession and reallowance figures appearing in the table below
the third paragraph under the caption &#147;Underwriting&#148; in the most recent Preliminary Prospectus and the Prospectus, and the statements in the first two paragraphs (including the bullet points between those paragraphs) of the subsection
entitled &#147;Price Stabilization, Short Positions and Penalty Bids&#148; under the caption &#147;Underwriting&#148; in the most recent Preliminary Prospectus and the Prospectus, constitute the only written information furnished to the Company by
the Representatives on behalf of the Underwriters, referred to in Sections&nbsp;1(e), 1(f), 1(g), 7(a) and 7(b) of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">13.&#8195;<I>Nature of Relationship</I>. The Company acknowledges and agrees that in connection with the offering and the sale of the Notes or
any other services the Underwriters may be deemed to be providing hereunder, notwithstanding any preexisting relationship, advisory or otherwise, between the parties or any oral representations or assurances previously or subsequently made by the
Underwriters: (i)&nbsp;no fiduciary or agency relationship between the Company and any other person, on the one hand, and the Underwriters, on the other hand, exists; (ii)&nbsp;the Underwriters are not acting as advisors, experts or otherwise, to
the Company, including, without limitation, with respect to the determination of the public offering price of the Notes, and such relationship between the Company, on the one hand, and the Underwriters, on the other hand, is entirely and solely a
commercial relationship, based on arms-length negotiations; (iii)&nbsp;any duties and obligations that the Underwriters may have to the Company shall be limited to those duties and obligations specifically stated herein; and (iv)&nbsp;the
Underwriters and their respective affiliates may have interests that differ from those of the Company. The Company hereby waives any claims that the Company may have against the Underwriters with respect to any breach of fiduciary duty in connection
with this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">14.&#8195;<I>Recognition of the U.S. Special Resolution Regime</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&#8195;In the event that any Underwriter is a Covered Entity and becomes subject to a proceeding under a U.S. Special Resolution Regime,
the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and
any such interest and obligation, were governed by the laws of the United States or a state of the United States.<I> </I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&#8195;In
the event that any Underwriter is a Covered Entity and it or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such
Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this Section&nbsp;14: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>BHC Act Affiliate</B>&#148; has the meaning assigned to the term
&#147;<B>affiliate</B>&#148; in, and shall be interpreted in accordance with, 12 U.S.C. &#167; 1841(k). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Covered
Entity</B>&#148; means any of the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&#8195;a &#147;covered entity&#148; as that term is defined in, and
interpreted in accordance with, 12 C.F.R. &#167; 252.82(b); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&#8195;a &#147;covered bank&#148; as that term is defined
in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&#8195;a &#147;covered FSI&#148; as that term is
defined in, and interpreted in accordance with, 12 C.F.R. &#167; 382.2(b).</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Default Right</B>&#148; has the meaning
assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>U.S. Special Resolution Regime</B>&#148; means each of (i)&nbsp;the Federal Deposit Insurance Act and the regulations
promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">15.&#8195;<I>Parties</I>. This Agreement will inure to the benefit of and be binding upon the several Underwriters, the Company and their
respective successors. This Agreement and the terms and provisions hereof are for the sole benefit of only those persons, except as specifically provided in Section&nbsp;7 of this Agreement. Nothing in this Agreement will be construed to give any
person, other than the persons referred to in this paragraph, any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision contained herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">16.&#8195;<I>Definition of </I><I>&#147;</I><I>Business Day</I><I>&#148;</I><I>.</I> For purposes of this Agreement, the term
&#147;<B>Business Day</B>&#148; means any day on which the New York Stock Exchange is open for trading, other than any day on which commercial banks are authorized or required to be closed in New York City. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">17.&#8195;<I>Governing Law</I>. This Agreement will be governed by, and construed in accordance with, the laws of the State of New York. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">18.&#8195;<I>Headings</I>. The headings herein are inserted for convenience of reference only and are not intended to be part of, or to affect
the meaning or interpretation of, this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">19.&#8195;<I>Counterparts</I>. This Agreement may be signed in one or more
counterparts, each of which will constitute an original and all of which together will constitute one and the same agreement. Counterparts may be delivered via facsimile, electronic mail (including any electronic signature covered by the U.S.
federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been
duly and validly delivered and be valid and effective for all purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Remainder of page intentionally left blank; Signatures
follow</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Please confirm, by signing and returning to us one or more counterparts of this Agreement,
that the foregoing correctly sets forth the Agreement between the Company and the several Underwriters. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">CVS HEALTH CORPORATION</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Tracy L. Smith</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tracy L. Smith</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Senior Vice President and Treasurer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Underwriting Agreement</I>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Confirmed and accepted as of the date first above mentioned </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">BARCLAYS CAPITAL INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Meghan Graper</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Meghan Graper</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>MD, Global Head of DCM</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">CITIGROUP GLOBAL MARKETS INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Adam D. Bordner</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Adam D. Bordner</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Managing Director</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">GOLDMAN SACHS&nbsp;&amp; CO. LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Karim Saleh</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Karim Saleh</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Managing Director</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Representatives and on behalf of the several Underwriters named in <U>Schedule I</U> hereto </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Underwriting Agreement</I>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>SCHEDULE I </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Underwriters</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Principal&nbsp;amount&nbsp;of&nbsp;the&nbsp;Series&nbsp;A<BR>Junior&nbsp;Subordinated&nbsp;Notes&nbsp;to&nbsp;be<BR>purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Principal&nbsp;amount&nbsp;of&nbsp;the&nbsp;Series&nbsp;B<BR>Junior&nbsp;Subordinated&nbsp;Notes&nbsp;to&nbsp;be<BR>purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Barclays Capital Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">292,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">292,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">292,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BofA Securities, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">225,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">225,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wells Fargo Securities, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">225,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mizuho Securities USA LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RBC Capital Markets, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Truist Securities, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">UBS Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. Bancorp Investments, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BNY Mellon Capital Markets, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fifth Third Securities, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Morgan Stanley&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PNC Capital Markets LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SMBC Nikko Securities America, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ICBC Standard Bank Plc</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">KeyBanc Capital Markets Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loop Capital Markets LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Piper Sandler&nbsp;&amp; Co.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R. Seelaus&nbsp;&amp; Co., LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TD Securities (USA) LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,250,000,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>750,000,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>SCHEDULE II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>ISSUER FREE WRITING PROSPECTUSES </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Final Term Sheet, dated December&nbsp;3, 2024, relating to the Notes, as filed pursuant to Rule 433 under the
Securities Act and attached as <U>Schedule III</U> hereto. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>SCHEDULE III </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRICING TERM SHEET </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>[Attached] </I></B></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CVS HEALTH CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Pricing Term Sheet&#151;December 3, 2024 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>$2,250,000,000 7.000% Series A Junior Subordinated Notes due 2055 </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>$750,000,000 6.750% Series B Junior Subordinated Notes due 2054 </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Issuer: </B></P></TD>
<TD>CVS Health Corporation (the &#147;<B>Issuer</B>&#148;) </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Description of Securities: </B></P></TD>
<TD>$2,250,000,000 7.000% Series A Junior Subordinated Notes due 2055 (the &#147;<B>Series A Junior Subordinated Notes</B>&#148;) </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">$750,000,000 6.750% Series B Junior Subordinated Notes due 2054 (the &#147;<B>Series B Junior Subordinated Notes</B>&#148; and, together with the Series A Junior Subordinated Notes, the &#147;<B>Notes</B>&#148;)
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Maturity Date: </B></P></TD>
<TD>March&nbsp;10, 2055 for the Series A Junior Subordinated Notes </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">December&nbsp;10, 2054 for the Series B Junior Subordinated Notes </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Settlement Date: </B></P></TD>
<TD>December&nbsp;10, 2024 (T+5). </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We expect to deliver the Notes against payment for the Notes on or about December&nbsp;10, 2024, which will be the fifth business day following the date of the pricing of the Notes. Under Rule <FONT
STYLE="white-space:nowrap">15c6-1</FONT> of the Exchange Act, trades in the secondary market generally are required to settle in one business day, unless the parties to a trade expressly agree otherwise. Accordingly, purchasers who wish to trade
Notes prior to the business day before the delivery of the notes hereunder will be required, by virtue of the fact that the Notes initially will settle in T+5, to specify alternative settlement arrangements to prevent a failed settlement.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Issue Price: </B></P></TD>
<TD>100.000% of principal amount for the Series A Junior Subordinated Notes </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">100.000% of principal amount for the Series B Junior Subordinated Notes </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Interest Payment Dates: </B></P></TD>
<TD>Subject to our right to defer the payment of interest on the Notes as described under &#147;Option to Defer Interest Payments&#148; in the preliminary prospectus supplement, we will pay interest on the Series A Junior Subordinated Notes
semi-annually in arrears on March 10&nbsp;and September 10&nbsp;of each year, beginning on March&nbsp;10, 2025, and on the Series B Junior Subordinated Notes on June 10&nbsp;and December 10&nbsp;of each year, beginning on June&nbsp;10, 2025.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Interest on the Notes offered hereby will accrue from December&nbsp;10, 2024. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>First Reset Date: </B></P></TD>
<TD>First Series A Reset Date: March&nbsp;10, 2030 </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">First Series B Reset Date: December&nbsp;10, 2034 </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Reset Date: </B></P></TD>
<TD>Series A Reset Date: First Series A Reset Date and March&nbsp;10 of every fifth year after 2030. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Series B Reset Date: First Series B Reset Date and December&nbsp;10 of every fifth year after 2034. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Interest Rate: </B></P></TD>
<TD> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Series A Junior Subordinated Notes will bear interest (i)&nbsp;from, and including, the original issuance date to, but excluding, March&nbsp;10,
2030 (&#147;First Series A Reset Date&#148;) at a rate of 7.000% per year and (ii)&nbsp;from, and including, the First Series A Reset Date, during each Reset Period, at a rate per year equal to the Five-year U.S. Treasury Rate as of the most recent
Reset Interest Determination Date plus a spread of 2.886%, to be reset on each Series A Reset </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:0%; font-size:10pt; font-family:Times New Roman">Date; provided that the interest rate during any Reset Period will not reset below 7.000% (which equals the initial interest rate on the
Series A Junior Subordinated Notes). </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The Series B Junior Subordinated Notes will bear interest (i)&nbsp;from, and including, the original issuance date to, but excluding, December&nbsp;10, 2034 (&#147;First Series B Reset Date&#148;) at a rate of 6.750%
per year and (ii)&nbsp;from, and including, the First Series B Reset Date, during each Reset Period, at a rate per year equal to the Five-year U.S. Treasury Rate as of the most recent Reset Interest Determination Date plus a spread of 2.516%, to be
reset on each Series B Reset Date; provided that the interest rate during any Reset Period will not reset below 6.750% (which equals the initial interest rate on the Series B Junior Subordinated Notes). </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Optional Deferral of Interest: </B></P></TD>
<TD>Up to 10 consecutive years per deferral </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Tax Event Call: </B></P></TD>
<TD>Each series of Notes is redeemable, in whole, but not in part, at 100% of the principal amount of the applicable series, plus accrued and unpaid interest to, but excluding, the redemption date, by a date no later than 120 days following the
occurrence of a Tax Event with respect to such series. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Rating Agency Event Call: </B></P></TD>
<TD>Each series of Notes is redeemable in whole but not in part, at 102% of the principal amount of the applicable series, plus accrued and unpaid interest to, but excluding, the redemption date, by a date no later than 120 days following a Rating
Agency Event with respect to such series. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Optional Redemption Provisions: </B></P></TD>
<TD>We may redeem the Series A Junior Subordinated Notes in whole or in part on one or more occasions at a price equal to 100% of the principal amount being redeemed, plus accrued and unpaid interest to, but excluding, the redemption date
(i)&nbsp;on any day during the period commencing on the date that is 90 days prior to the First Series A Reset Date and ending on and including the First Series A Reset Date and (ii)&nbsp;after the First Series A Reset Date, on any interest payment
date for the Series A Junior Subordinated Notes. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We may redeem the Series B Junior Subordinated Notes in whole or in part on one or more occasions at a price equal to 100% of the principal amount being redeemed, plus accrued and unpaid interest to, but excluding, the
redemption date (i)&nbsp;on any day during the period commencing on the date that is 90 days prior to the First Series B Reset Date and ending on and including the First Series B Reset Date and (ii)&nbsp;after the First Series B Reset Date, on any
interest payment date for the Series B Junior Subordinated Notes. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Joint Book-Running Managers: </B></P></TD>
<TD>BARCLAYS CAPITAL INC. </TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:38%; font-size:10pt; font-family:Times New Roman">CITIGROUP GLOBAL MARKETS INC. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:38%; font-size:10pt; font-family:Times New Roman">GOLDMAN SACHS&nbsp;&amp; CO. LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:38%; font-size:10pt; font-family:Times New Roman">BOFA SECURITIES, INC. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:38%; font-size:10pt; font-family:Times New Roman">J.P.
MORGAN SECURITIES LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:38%; font-size:10pt; font-family:Times New Roman">WELLS FARGO SECURITIES, LLC </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Co-Managers:</FONT> </B></P></TD>
<TD>MIZUHO SECURITIES USA LLC </TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:38%; font-size:10pt; font-family:Times New Roman">RBC CAPITAL MARKETS, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:38%; font-size:10pt; font-family:Times New Roman">TRUIST SECURITIES, INC. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:38%; font-size:10pt; font-family:Times New Roman">UBS
SECURITIES LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:38%; font-size:10pt; font-family:Times New Roman">U.S. BANCORP INVESTMENTS, INC. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:38%; font-size:10pt; font-family:Times New Roman">BNY MELLON CAPITAL MARKETS, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:38%; font-size:10pt; font-family:Times New Roman">FIFTH THIRD SECURITIES, INC. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:38%; font-size:10pt; font-family:Times New Roman">MORGAN STANLEY&nbsp;&amp; CO. LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:38%; font-size:10pt; font-family:Times New Roman">PNC CAPITAL MARKETS LLC </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:0%; font-size:10pt; font-family:Times New Roman">SMBC NIKKO SECURITIES AMERICA, INC. </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:38%; font-size:10pt; font-family:Times New Roman">ICBC STANDARD BANK PLC<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:38%; font-size:10pt; font-family:Times New Roman">KEYBANC CAPITAL MARKETS INC. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:38%; font-size:10pt; font-family:Times New Roman">LOOP CAPITAL MARKETS LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:38%; font-size:10pt; font-family:Times New Roman">PIPER
SANDLER&nbsp;&amp; CO. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:38%; font-size:10pt; font-family:Times New Roman">R. SEELAUS&nbsp;&amp; CO., LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:38%; font-size:10pt; font-family:Times New Roman">TD SECURITIES (USA) LLC </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>CUSIP Number: </B></P></TD>
<TD>Series A Junior Subordinated Notes: 126650 EH9 </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Series B Junior Subordinated Notes: 126650 EG1 </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Ratings*: </B></P></TD>
<TD>[Reserved] </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>*</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Note: A securities rating is not a recommendation to buy, sell or hold securities and may be subject to
revision or withdrawal at any time. </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ICBC Standard Bank Plc is restricted in its U.S. securities dealings under the United States Bank Holding
Company Act and may not underwrite, subscribe, agree to purchase or procure purchasers to purchase notes that are offered or sold in the United States. Accordingly, ICBC Standard Bank Plc shall not be obligated to, and shall not, underwrite,
subscribe, agree to purchase or procure purchasers to purchase notes that may be offered or sold by other underwriters in the United States. ICBC Standard Bank Plc shall offer and sell the Notes constituting part of its allotment solely outside the
United States. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This pricing term sheet should be read together with the Issuer&#146;s preliminary prospectus supplement dated December&nbsp;3, 2024, the accompanying
prospectus dated May&nbsp;25, 2023 and the other documents incorporated by reference therein. Capitalized terms used but not defined herein have the meanings given to them in the preliminary prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Issuer has filed a registration statement (including a prospectus and preliminary prospectus supplement) with the SEC for the offering to which this
communication relates. Before you invest, you should read the prospectus and preliminary prospectus supplement in that registration statement, and other documents the Issuer has filed with the SEC for more complete information about the Issuer and
this offering. You may get these documents for free by visiting EDGAR on the SEC website at<U> </U></B><B><I><U>www.sec.gov</U></I></B><B><U></U>. Alternatively, you may obtain a copy of the prospectus and the preliminary prospectus supplement from
Barclays Capital Inc. by calling toll-free at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-888-603-5847,</FONT></FONT></FONT> Citigroup Global Markets Inc. by calling toll-free at <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-831-9146</FONT></FONT></FONT> and Goldman Sachs&nbsp;&amp; Co. LLC by calling toll-free at <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-866-471-2526.</FONT></FONT></FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ANY DISCLAIMERS OR OTHER NOTICES THAT MAY APPEAR
BELOW ARE NOT APPLICABLE TO THIS COMMUNICATION AND SHOULD BE DISREGARDED. SUCH DISCLAIMERS OR OTHER NOTICES WERE AUTOMATICALLY GENERATED AS A RESULT OF THIS COMMUNICATION BEING SENT VIA BLOOMBERG OR ANOTHER EMAIL SYSTEM. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SIGNIFICANT SUBSIDIARIES </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As used
in the Underwriting Agreement, the &#147;Significant Subsidiaries&#148; of the Company are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Name</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Jurisdiction&nbsp;of&nbsp;Organization</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">%&nbsp;Owned</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Liens/Encumbrances</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aetna Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Pennsylvania</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CVS Pharmacy, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Rhode Island</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Caremark, L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>California</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CaremarkPCS Health, L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Delaware</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Caremark Rx, L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Delaware</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CVS Caremark Part D Services, L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Delaware</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SilverScript Insurance Company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tennessee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>cvs-20241203.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241008.3 -->
<!-- Creation date: 12/5/2024 4:43:54 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2023"
  xmlns:cvs="http://www.cvshealth.com/20241203"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.cvshealth.com/20241203"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" namespace="http://xbrl.sec.gov/naics/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cvs-20241203_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cvs-20241203_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.cvshealth.com//20241203/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>cvs-20241203_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241008.3 -->
<!-- Creation date: 12/5/2024 4:43:54 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>cvs-20241203_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241008.3 -->
<!-- Creation date: 12/5/2024 4:43:54 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cvshealth.com//20241203/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="cvs-20241203.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cvshealth.com//20241203/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g910747g1204104159153.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g910747g1204104159153.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  4 &D# 2(  A$! Q$!_\0
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45797445191936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Dec. 03, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CVS HEALTH Corp<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000064803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec.  03,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-01011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">05-0494040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One CVS Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Woonsocket<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">RI<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02895<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(401)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">765-1500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CVS<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M#Z[2R=.8/<.=>JY%F1X!,ZQ:M&%O _O"+^OU@?KA>EUD0>/Z 6[1WY'-C"F
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MP %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @ G9:$69>*NQS     $P(
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MB^$_7G\!4$L! A0#%     @ G9:$60=!36*!    L0   !
M ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "=EH19A!].9.\
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M<W1Y;&5S+GAM;%!+ 0(4 Q0    ( )V6A%F7BKL<P    !,"   +
M      "  5\/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( )V6A%D<.&7J/P$
M #P"   /              "  4@0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M    " "=EH19)!Z;HJT   #X 0  &@              @ &T$0  >&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "=EH1999!YDAD!  #/
M P  $P              @ &9$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
1    "0 ) #X"  #C$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d910747d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com//20241203/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cvs-20241203.xsd</File>
    <File>cvs-20241203_lab.xml</File>
    <File>cvs-20241203_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="d910747d8k.htm">d910747d8k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g910747g1204104159153.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d910747d8k.htm": {
   "nsprefix": "cvs",
   "nsuri": "http://www.cvshealth.com/20241203",
   "dts": {
    "schema": {
     "local": [
      "cvs-20241203.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "cvs-20241203_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cvs-20241203_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "d910747d8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://www.cvshealth.com//20241203/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2024-12-03_to_2024-12-03",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d910747d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2024-12-03_to_2024-12-03",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d910747d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.cvshealth.com//20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.cvshealth.com//20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.cvshealth.com//20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.cvshealth.com//20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.cvshealth.com//20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.cvshealth.com//20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.cvshealth.com//20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.cvshealth.com//20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.cvshealth.com//20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.cvshealth.com//20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.cvshealth.com//20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.cvshealth.com//20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.cvshealth.com//20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.cvshealth.com//20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.cvshealth.com//20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.cvshealth.com//20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.cvshealth.com//20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.cvshealth.com//20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.cvshealth.com//20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.cvshealth.com//20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.cvshealth.com//20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.cvshealth.com//20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001193125-24-270867-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-24-270867-xbrl.zip
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M6M5+B&)73?MU0_)<Q#S>?&8S;@J)^)._8'7)M.=V!&BE$2R/<<&U7(^(VK0
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MLQ?&\D*05H*L%-%K?"W:L+S(5]=+\<25/C)_=R([Q=._OJ#/_ =02P,$%
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MP\/VPKUM';#F2?-PKU Y[W7S^@%O9.A/E[P8R7:E4B@?PZZ,J ]>P;>SMZ)
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M_14LB+RI \H&+#.^&!1XV(>5 5Z(P6-_3%];&3.O8$5XOG'8--(H$#I,?.W
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MWH[Z8#,VK".301G'9@41#J"!E@VDVL(S0,Y?D40DG8S5,U1E88M1/X+7#,,
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MR,YL'0=6S]56ABKBP/X.Y)SIF_H-ZP%,%+[X\4$[HO$M9H., Z766'Z5&,B
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M(:-+ V992ZC+.M/;Q7%/PAQ=:5(-TEC*@?JB@-4I J#L%.G.(_4,TG1:GMF
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M %!+ 0(4 Q0    ( )V6A%E/NOR3/@,  $P+   0              "  0
M  !C=G,M,C R-#$R,#,N>'-D4$L! A0#%     @ G9:$60XDSP=@!@  OD,
M !0              ( !; ,  &-V<RTR,#(T,3(P,U]L86(N>&UL4$L! A0#
M%     @ G9:$62%S<]RT!   ?2H  !0              ( !_@D  &-V<RTR
M,#(T,3(P,U]P<F4N>&UL4$L! A0#%     @ G9:$6>$TF@^"$P  UW,   X
M             ( !Y X  &0Y,3 W-#=D.&LN:'1M4$L! A0#%     @ G9:$
M6=8M)+T,:@  FH " !               ( !DB(  &0Y,3 W-#=D97@Q,2YH
M=&U02P$"% ,4    " "=EH192JDO31$%  "@!0  &0              @ ',
MC   9SDQ,#<T-V<Q,C T,3 T,34Y,34S+FIP9U!+!08     !@ & (,!   4
%D@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>d910747d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cvs-20241203.xsd" xlink:type="simple"/>
    <context id="duration_2024-12-03_to_2024-12-03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
        </entity>
        <period>
            <startDate>2024-12-03</startDate>
            <endDate>2024-12-03</endDate>
        </period>
    </context>
    <dei:EntityRegistrantName
      contextRef="duration_2024-12-03_to_2024-12-03"
      id="Hidden_dei_EntityRegistrantName">CVS HEALTH Corp</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="duration_2024-12-03_to_2024-12-03" id="ixv-280">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2024-12-03_to_2024-12-03"
      id="Hidden_dei_EntityCentralIndexKey">0000064803</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2024-12-03_to_2024-12-03" id="ixv-291">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2024-12-03_to_2024-12-03" id="ixv-292">2024-12-03</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2024-12-03_to_2024-12-03" id="ixv-293">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2024-12-03_to_2024-12-03" id="ixv-294">001-01011</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2024-12-03_to_2024-12-03" id="ixv-295">05-0494040</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2024-12-03_to_2024-12-03" id="ixv-296">One CVS Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2024-12-03_to_2024-12-03" id="ixv-297">Woonsocket</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2024-12-03_to_2024-12-03" id="ixv-298">RI</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2024-12-03_to_2024-12-03" id="ixv-299">02895</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2024-12-03_to_2024-12-03" id="ixv-300">(401)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2024-12-03_to_2024-12-03" id="ixv-301">765-1500</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2024-12-03_to_2024-12-03" id="ixv-302">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2024-12-03_to_2024-12-03" id="ixv-303">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2024-12-03_to_2024-12-03" id="ixv-304">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2024-12-03_to_2024-12-03" id="ixv-305">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2024-12-03_to_2024-12-03" id="ixv-306">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2024-12-03_to_2024-12-03" id="ixv-307">CVS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2024-12-03_to_2024-12-03" id="ixv-308">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2024-12-03_to_2024-12-03" id="ixv-309">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
